---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064423"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:56:55.492120+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reports Q1 net loss $28.2M ($0.31/sh); cash $150.4M; expects data readouts in 2H 2025

## Summary
- Net loss $28.2M ($0.31 per share) vs $28.0M loss in Q1 2024; R&D spending $22.8M.
- Cash $150.4M as of Mar 31, 2025; company expects to fund operations into 2H 2026.
- Phase 1 trial of ADI-001 in autoimmune diseases expanded to LN/SLE; preliminary data expected 2H 2025.
- Phase 1 trial of ADI-270 in metastatic/advanced ccRCC ongoing; preliminary data expected 2H 2025.
- Michael Grissinger appointed to board; FDA granted Fast Track for ADI-001 in SLE and SSc.

## SEC filing metadata
- accession: 0000950170-25-064423
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025064423/0000950170-25-064423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025064423/acet-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064423
- JSON: https://secwatch.observer/filing/0000950170-25-064423.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.